Exosens
€59.20Change from previous close: +0.17%Absolute change: +€0.10
At a glance
- Revenue growth
- −18.11%
- 2025 vs 2024
- Net income growth
- −28.10%
- 2025 vs 2024
- Net margin
- 8.0%
- 2024: 9.1%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 383 | 468 | 292 | 201 | — |
| Cost of revenue | 161 | 191 | 80.3 | 86.8 | — |
| Gross profit | 222 | 278 | 212 | 114 | — |
| Operating income | 80.6 | 102 | 54.6 | 33.0 | — |
| EBIT | 80.6 | 102 | 47.2 | 32.3 | — |
| EBITDA | 120 | 142 | 75.3 | 51.2 | — |
| Interest expense | — | — | 26.9 | 15.2 | 37.6 |
| Pre-tax income | 45.8 | 88.2 | 20.2 | 17.1 | — |
| Income tax | 11.6 | 18.0 | 1.8 | 5.9 | — |
| Net income | 30.7 | 42.7 | 18.4 | 11.2 | — |
| Net income to common shareholders | 30.7 | 42.7 | 7.4 | 11.2 | — |
| Basic EPS | 0.61 | 0.84 | 0.24 | 0.37 | — |
| Diluted EPS | 0.61 | 0.84 | 0.24 | 0.37 | — |
| Average shares (basic) | 50.7 | 50.8 | 30.4 | 30.4 | — |
| Average shares (diluted) | 50.7 | 50.8 | 30.4 | 30.4 | — |